Valuing a startup is not a smaller version of valuing an established business. The methods that work on a profitable company all begin with the same raw material: a history of earnings. A startup does not have one. What it has instead is a team, a market, a product at some stage of completion, and a forecast. Startup valuation is the discipline of turning that thinner evidence into a number someone will stand behind.
Nowhere is that discipline tested harder than in Silicon Valley. Rounds close quickly, cap tables change often, and a company can move through three valuation stages in the time a business elsewhere takes to complete one. Founders between Palo Alto and San Jose are not choosing a method once. They are re-choosing it every time the evidence base shifts underneath them.
The short answer: the right startup valuation method is determined by the evidence you actually have, and the evidence you have is determined by your stage. Pre-revenue companies are valued with comparison-based methods such as Berkus and Scorecard, which benchmark qualitative strengths against comparable funded startups. Revenue-stage companies move to market multiples and the venture capital method. Companies with forecasts a buyer would believe can support a discounted cash flow analysis. Most credible valuations use two or three methods and reconcile them, rather than relying on one.
Key takeaways
- The method follows the evidence, and the evidence follows the stage. Applying a DCF to a pre-seed company produces a number with no support underneath it.
- Purpose changes the answer. A fundraising valuation, a 409A valuation, and an M&A valuation of the same company will produce three different, defensible figures.
- Pre-revenue methods such as Berkus and Scorecard are comparison frameworks, not calculations. Their output is only as good as the comparable set behind them.
- Common stock is normally worth less than the preferred stock investors just bought, which is why your round price cannot be used as your option strike price.
- Nearly every valuation that collapses in diligence collapses for the same reason: the assumptions were never documented at the time they were made.
- In fast-moving markets such as Silicon Valley, the method that fitted your company at the last round may already be the wrong one, because the evidence base moves faster than the calendar.
"What is my startup worth?" is the wrong question
What you have to work with at each stage to perform a start valuation?
Think of your company’s history as a ladder of evidence. Each rung adds something an appraiser can point to, and each new rung opens up a method that was unusable before.
At pre-seed you have a founding team, a market you can size, and possibly a prototype. There is nothing to discount and nothing to multiply, so valuation at this stage is fundamentally an act of structured comparison against other companies that raised at a similar point.
At seed and Series A, early revenue appears. Now there is something to measure: growth rate, customer concentration, retention, gross margin. Market multiples become available because you finally have a denominator.
By Series B, the operating history is long enough that unit economics stabilize and cohort behaviour becomes predictable. Forecasts stop being aspiration and start being extrapolation, which is the point at which a discounted cash flow analysis earns real weight.
At Series C and beyond, you are valued much like a mature company, with the caveat that growth still dominates. In fast-moving ecosystems, and Silicon Valley startup valuation work is the clearest example, companies can climb this ladder in eighteen months, which means the method that fit last year may not fit today.
The six methods, and what each one is blind to
Every method has a failure mode. Knowing what a method cannot see is more useful than knowing how to run it.
The Berkus method
The Scorecard method
The Scorecard method
Scorecard starts from the average pre-money valuation of recently funded startups in your region and sector, then adjusts up or down across weighted factors: management strength, opportunity size, product and technology, competitive environment, marketing and sales channels, need for further investment, and other considerations.
What it is good at: anchoring to real market data rather than to an abstract framework, which makes it far easier to defend.
What it is blind to: everything absent from your comparable set. If the recent local rounds you are benchmarking against were priced in an unusually hot or cold window, that distortion passes straight into your number. The method also assumes you can observe those averages accurately, which is often the hardest part.
The venture capital method
The VC method works backward. Estimate an exit value, decide the return multiple an investor needs, discount back to today, then subtract the investment to reach a pre-money valuation.
What it is good at: reflecting the actual economics of the person writing the cheque, which makes it the closest thing to how a round is really priced.
What it is blind to: the reliability of the exit assumption, which is doing almost all the work. It also tends to understate dilution across future rounds unless you explicitly model them.
Comparable companies and precedent transactions
Apply revenue or earnings multiples drawn from similar public companies or recent private deals in your sector.
What it is good at: grounding the valuation in observable market pricing, which is the evidence auditors and investors find most persuasive.
What it is blind to: whether your peers are genuinely comparable. Growth rate, gross margin, retention, and capital intensity all move multiples sharply. A peer set chosen for aspiration rather than similarity is the single most common defect we see in founder-built valuations.
Discounted cash flow
Project free cash flows over a forecast period, apply a terminal value, and discount everything back at a rate reflecting risk.
What it is good at: forcing every assumption into the open. A DCF cannot hide what it believes about growth, margin, and risk.
What it is blind to: nothing, in principle, which is precisely the problem at early stage. The output is entirely a function of inputs, so a DCF built on a forecast with no operating history behind it produces false precision. Used as a supporting method at Series A and as a primary method from Series B onward, it is genuinely strong.
PWERM and the First Chicago approach
Rather than valuing one future, these methods value several. You build distinct scenarios such as a strong exit, a modest exit, and a wind-down, value each, assign probabilities, and take the weighted result.
What it is good at: capturing the binary or milestone-driven reality of companies where the outcome distribution is genuinely lumpy. It is also the standard approach for allocating value across share classes in a 409A context.
What it is blind to: the honesty of your probabilities. Scenario weights are the easiest place in any valuation to quietly embed optimism, which is why they need explicit support.
Which method fits which stage
Use this as a starting map rather than a rule. The correct answer is always driven by the specific facts of the company.
|
Stage
|
Evidence available
|
Primary method
|
Supporting method
|
Most common failure
|
|---|---|---|---|---|
|
Pre-seed / Seed
|
Team, market size, prototype, first users
|
Scorecard, Berkus
|
VC method
|
Comparable set is too small or too stale to defend
|
|
Series A
|
Early revenue, growth rate, first retention data
|
VC method, revenue multiples
|
Early DCF
|
Peers chosen for aspiration rather than similarity
|
|
Series B
|
Stable unit economics, cohort behaviour, margin trend
|
Revenue or EBITDA multiples, DCF
|
Precedent transactions
|
Forecast extends well past what cohorts actually support
|
|
Series C+
|
Multi-year operating history, credible path to profit
|
DCF, comparable companies
|
Precedent transactions, PWERM
|
Terminal value assumptions carrying too much of the answer
|
Not sure which method your stage supports?
CountSure works with founders, CFOs, and investors across the US to build valuations that hold up in diligence.
Why your round valuation and your 409A valuation will not match
Founders are regularly surprised to learn that the company they just raised at a headline valuation of, say, sixty million dollars has a common-stock fair market value far below that. This is not an error. It is the structure working as intended.
Investors buy preferred stock, which carries rights common stock does not: a liquidation preference that pays them first, often participation rights, sometimes anti-dilution protection, and typically board and consent rights. Those rights have value. Strip them out and what remains, the common stock your employees hold options over, is worth less.
Reaching that common-stock figure requires an allocation model, usually an option-pricing model or a probability-weighted expected return method, that distributes enterprise value across your share classes according to their rights. That allocation is the substantive work in a 409A engagement, and it is the part a spreadsheet estimate cannot replicate.
An independent appraisal performed by a qualified professional is also what supports safe harbor treatment under Internal Revenue Code Section 409A, which shifts the burden of proof to the IRS if your valuation is ever challenged. That protection generally runs for twelve months from the valuation date, or until a material event occurs, whichever comes first. In high-velocity markets such as Silicon Valley’s unicorn ecosystem, the material event almost always arrives before the anniversary does.
Where founder-built valuations fall apart in diligence
We are frequently brought in to repair a valuation rather than build one. The failures cluster into five patterns.
The peer set was chosen for aspiration
Benchmarking a fifteen-person company against listed sector leaders is the fastest way to lose a room. Comparability means similar growth, margin, retention, and capital intensity, not similar ambition.
The forecast has no cohort data behind it
A revenue curve that triples annually for five years is not a forecast unless something in your existing customer behaviour supports it. Diligence teams test forecasts against retention and expansion data first, and the gap between the two is where credibility is lost.
The option pool was left out of pre-money
Investors typically require the unallocated option pool to sit inside the pre-money valuation, which means founders absorb that dilution rather than sharing it. Modelling the round without it produces an ownership picture that will not survive the term sheet.
A SAFE cap was treated as a valuation
A valuation cap sets a ceiling on the price at which a SAFE or note converts. It is a negotiated term, not an appraisal, and it does not establish fair market value for any other purpose.
The discount rate was never justified
A discount rate is the most consequential single input in any income-based method, and it is also the one most often stated without support. If the report cannot explain where the rate came from, the entire conclusion is exposed.
Need a valuation that survives investor and auditor scrutiny?
Talk to the CountSure valuation team.
Frequently Asked Questions
1. How do you value a startup with no revenue?
2.What is the most accurate startup valuation method?
3. What is the difference between the Berkus and Scorecard methods?
4. Can I use a DCF for an early-stage startup?
5. Why is my 409A valuation lower than my funding round valuation?
6. How often should a startup update its valuation?
At least annually for 409A purposes, and sooner if a material event occurs first, such as a priced round, a significant SAFE or note conversion, a secondary transaction, or a major business milestone.
7. Does a SAFE valuation cap set my company's valuation?
No. A valuation cap is a negotiated ceiling on the conversion price of that instrument. It is not an independent appraisal and does not establish fair market value for option pricing, tax, or reporting purposes.
8. Are Silicon Valley startups valued differently from startups elsewhere?
The methods are the same, but the inputs and the cadence differ. Bay Area comparable sets price at a premium to national averages, rounds close faster so valuations go stale sooner, and employee tender offers create observable secondary prices that an appraiser has to address. The result is that the same method, applied honestly, produces a different number and needs refreshing more often.
9. Who should perform a startup valuation?
For anything with tax, audit, or regulatory consequences, a credentialed and independent valuation professional. Independent appraisal by a qualified professional is what supports IRS safe harbor treatment for 409A purposes, and independence from the transaction is what gives the number weight with investors and auditors.
Parth Shah, Managing Director
(CPA-US, FCA, RV-S&FA, DISA)
Parth Shah who is head of Accounts and Book keeping has experience of more than 10 years. A Certified Public Accountant – US, fellow Chartered Accountant, Registered Valuer and Diploma in Information System Audit.
